Gyre Therapeutics (NASDAQ:GYRE) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Is Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE Of 8.6% Concerning? [Yahoo! Finance]
Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update
Gyre Therapeutics (NASDAQ:GYRE) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis